OncoPharm

John Bossaer

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

  1. BR.31 & ASCO GU '26

    -6 DIAS

    BR.31 & ASCO GU '26

    This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022) Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

    18 min
  2. Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia

    26/02

    Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia

    An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2 Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

    16 min
  3. Perioperative Enortumab vedotin + Pembrolizumab

    19/02

    Perioperative Enortumab vedotin + Pembrolizumab

    The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

    17 min
  4. Axi-Cel and 5-FU Label Changes

    12/02

    Axi-Cel and 5-FU Label Changes

    We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

    13 min

  5. 5/02

    Core Communication Skills in Chemotherapy Education

    A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

    15 min
  6. PATINA

    29/01

    PATINA

    Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

    16 min
  7. Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    22/01

    Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

    18 min
  8. Oncology Drug Use Evolution

    15/01

    Oncology Drug Use Evolution

    This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

    11 min
Ver tudo (417)

Sobre

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Informação

  • Autoria
    John Bossaer
  • Anos em atividade
    2017 - 2026
  • Episódios
    417
  • Classificação
    Para todos
  • Copyright
    © All rights reserved
  • Site do programa
    OncoPharm

Talvez também goste